| Authors: |
Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Vajdi A; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Mu XJ; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Ngo K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and., Okoro JJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Xu M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Springer BF; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Eschle BK; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Messier CM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Wang S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Syamala S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and., Tamen RM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Adeni AE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Canadas I; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Thai T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Christensen CL; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Xu C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Oxnard GR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Watanabe H; Catherine and Henry J. Gaisman Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine.; Tisch Cancer Institute; and.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and., Gokhale PC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. |
